Promising combo therapy targets aggressive lymphoma in young patients
NCT ID NCT02427620
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a combination of targeted therapy (ibrutinib) and immunotherapy (rituximab) followed by strong chemotherapy in young patients with newly diagnosed mantle cell lymphoma, an aggressive blood cancer. The goal is to see if this approach improves response rates while managing side effects. About 131 participants will receive the treatment in a specific order to maximize cancer cell killing.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BLASTOID VARIANT MANTLE CELL LYMPHOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
M D Anderson Cancer Center
Houston, Texas, 77030, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- A shot at safer CAR t: early brain protection for lymphoma patients?
- Engineered immune cells take aim at Hard-to-Treat lymphomas
- Can donor immune cells be engineered to fight blood cancer?
- Can a cancer drug reboot the immune system after a stem cell transplant?
- Can a targeted drug boost standard chemo for a rare blood cancer?
- Smartwatches track hidden heart risk in blood cancer patients